Streetbeat News

Revenues

MVPA

OCTA

TTE

TotalEnergies SE shares are rising after winning a tender for LNG supply in Greece and securing a mid-term LNG deal with Santos. The company anticipates 3% annual growth in Oil & Gas production through 2030, driven by LNG projects.

Portfolio Pulse from Lekha Gupta

October 04, 2024 | 4:49 pm

IREN

Iris Energy shares rose following the announcement that the company mined 347 Bitcoin in September.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:35 pm

AAPL

AMZN

GOOG

META

MSFT

NVDA

QQQ

SPY

TSLA

The recent jobs report exceeded expectations, leading to a stock market rally and aggressive buying in AI stocks. The report challenges the Fed's recent interest rate cut, suggesting no labor weakness. Positive money flows are observed in major tech stocks and ETFs like SPY and QQQ.

Portfolio Pulse from The Arora Report

October 04, 2024 | 4:05 pm

WBD

Warner Bros. Discovery's top advertising executive, Jon Steinlauf, is leaving the company. This departure could impact the company's advertising strategy and revenue generation in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 4:03 pm

TELA

TELA Bio (NASDAQ:TELA) has been the subject of recent analyst reviews, with 6 analysts providing ratings ranging from bullish to bearish. The average 12-month price target has decreased by 16.48% to $11.0. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. TELA Bio, a medical technology company, has shown revenue growth but faces challenges with profitability, debt management, and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

EE

Analysts have mixed ratings for Excelerate Energy (NYSE:EE), with recent price targets averaging $21.2, reflecting a slight increase. The company's financial performance shows challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

NBIX

Neurocrine Biosciences (NASDAQ:NBIX) has received diverse analyst ratings over the past three months, with a mix of bullish and bearish outlooks. Analysts have set a 12-month average price target of $166.7, reflecting a 2.93% increase from the previous target. The company's financial performance is strong, with significant revenue growth and profitability metrics exceeding industry averages.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:01 pm

META

Meta Platforms Inc. has launched Movie Gen, a generative AI tool for creating videos, images, and audio from text prompts. This innovation is part of Meta's strategy to enhance user engagement and product adoption, potentially driving revenue growth.

Portfolio Pulse from Michael Cohen

October 04, 2024 | 4:01 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has been evaluated by 13 analysts, showing a mix of bullish and bearish perspectives. The average 12-month price target is $17.38, a 21.53% decrease from the previous target. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Sage Therapeutics is a clinical-stage biopharmaceutical company focusing on brain health medicines, with significant revenue growth but challenges in asset utilization.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm

CBRE

Analysts have varied ratings for CBRE Group, ranging from bullish to bearish. Recent analyst actions show raised price targets and ratings, indicating positive sentiment. CBRE's financials reveal strong market position, revenue growth, and profitability, with efficient debt management.

Portfolio Pulse from Benzinga Insights

October 04, 2024 | 4:00 pm